Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 - GBI Research Reports

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 - GBI Research Reports
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Published Nov 01, 2011
230 pages — Published Nov 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimers disease, multiple sclerosis, Parkinsons disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimers disease, multiple sclerosis, Parkinsons disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.

Scope

- Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Tev

  
Source:
Document ID
GBIHC130MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents411
  List of Tables84
  List of Figures123
CNS Disorder Therapeutic Market to 2017 - Introduction151
  GBI Research Report Guidance151
CNS Disorder Therapeutic Market to 2017 - Global Market Overview169
  Introduction161
  Revenue171
    Generic Share181
    Annual Cost of Treatment191
  Top CNS Drug Products201
    Seroquel (IR/XR) (quetiapine fumarate)201
    Zyprexa (olanzapine)201
    Cymbalta (duloxetine Hcl)211
    Copaxone (glatiramer acetate)211
    Lyrica (pregabalin)221
    Abilify (aripiprazole)221
    Avonex (Interferon beta-1a)231
    Rebif (interferon beta-1a)231
    Effexor (venlafaxine)231
    Betaferon /Betaseron (Interferon beta-1b)241
CNS Disorder Therapeutic Market to 2017 - Geographical Landscape258
  Revenue Analysis by Geography251
  The US261
    Revenue261
    Annual Cost of Treatment271
  Top Five Countries of Europe281
    Revenue282
    Annual Cost of Treatment301
  Japan311
    Revenue311
    Annual Cost of Treatment321
CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape33105
    Introduction331
      Treatment Algorithm341
    Revenue353
      Generic Share381
    Annual Cost of Treatment391
    Treatment Usage Patterns401
      Diseased Population411
      Treatment Seeking Population411
      Diagnosis Population411
      Prescription Population411
      Geriatric Population Growth and Increased Life Expectancy421
      Expected Launch of New Drugs Will Drive the Alzheimer s disease Market In Future421
      Low Diagnosis Rate Reduces Number of Patients on AD Drug Therapy.431
      Slow Drug Development Programs and Recent Drug Failures Will Hamper Development of Promising Molecules.431
  Attention Deficit Hyperactivity Disorder (ADHD)431
    Introduction431
      Treatment Algorithm441
    Revenue452
      Revenue by Country471
      Generic Share481
    Annual Cost of Treatment491
    Treatment Usage Patterns501
      Diseased Population511
      Treatment Seeking Population511
      Diagnosis Population511
      Prescription Population511
  Drivers and Barriers to ADHD Market521
    Drivers for ADHD Market521
      Increase in Diseased Population521
    Barriers for ADHD Market521
      Misdiagnosis of ADHD is a Growing Concern521
      Drug Side Effects and Alternative Options521
      Patent Expiries of Major Drugs531
  Bipolar Disorder531
    Introduction531
      Treatment Algorithm541
    Revenue551
      Revenue by Country561
      Generic Share571
    Annual Cost of Treatment581
    Treatment Usage Patterns591
      Diseased Population601
      Treatment Seeking Population601
      Diagnosis Population601
      Prescription Population601
  Drivers and Barriers to Bipolar Disorder Market611
    Drivers for Bipolar Disorder Market611
      Increase in Patient Volume May Drive Market Growth in Future611
    Barriers for Bipolar Disorder Market611
      Patent Expiries of the Leading Anticonvulsants and Upcoming Patent Expiries of Antipsychotics611
      Low Diagnosis Rate of Bipolar Disorder611
      Prescription Rates are Higher for Lithium621
  Diabetic Neuropathy621
    Introduction621
      Treatment Algorithm631
    Revenue641
      Revenue by Country651
      Generic Share661
    Annual Cost of Treatment671
    Treatment Usage Pattern681
      Diseased Population691
      Treatment Seeking Population691
      Diagnosis Population691
      Prescription Population691
  Drivers and Restraints to Diabetic Neuropathy Market701
    Drivers for Diabetic Neuropathy Market701
      Expected Launch of New Molecules Will Drive the Diabetic Neuropathy Therapeutics Market Growth in Future701
      Increasing Diseased Population701
    Restraints for the Diabetic Neuropathy Therapeutics Market701
      Patent Expiry of Drugs Such as Cymbalta and Lyrica701
  Epilepsy711
    Introduction711
      Treatment Algorithm711
    Revenue721
      Revenue by Country731
      Generic Share741
    Annual Cost of Treatment751
    Treatment Usage Patterns761
      Diseased Population771
      Treatment Seeking Population771
      Diagnosis Population771
      Prescription Population771
  Drivers and Barriers to Epilepsy Market781
    Drivers for Epilepsy Market781
      Expected Launch of New Drugs Will Drive the Epilepsy Market781
      Rise in Geriatric Population781
    Barriers to Epilepsy Market781
      Patent Expiry of the Leading Anticonvulsants781
  Insomnia791
    Introduction791
      Treatment Algorithm801
    Revenue811
      Revenue by Country821
      Generic Share831
    Annual Cost of Treatment841
    Treatment Usage Patterns851
      Diseased Population861
      Treatment Seeking Population861
      Diagnosis Population861
      Prescription Population861
  Drivers and Barriers to Insomnia Market871
    Drivers for Insomnia Market871
      Aging population871
      High Increase in Obese Population871
    Barriers for Insomnia Market881
      Weak Pipeline Portfolio for Insomnia881
      Low Cost Treatments Suppress the Market881
  Migraine881
    Introduction881
      Treatment Algorithm891
    Revenue901
      Revenue by Country912
      Generic Share931
    Annual Cost of Treatment941
    Treatment Usage Patterns952
      Diseased Population971
      Treatment Seeking Population971
      Diagnosis Population971
      Prescription Population971
  Drivers and Barriers for Migraine Market981
    Drivers for Migraine Market981
      The Increasing Awareness Will Result in Increasing Prescription Rate981
    Barriers for Migraine Market991
      Low Treatment Seeking Behavior and Diagnosis Rate Restrain Growth in Prescription Population991
      Falling Prices of Migraine Treatment Will Restrain the Market by Off-setting the Impact of Increasing Volume991
  Multiple Sclerosis991
    Introduction992
      Treatment algorithm1011
    Revenue1022
      Revenue by Country1041
      Generic Share1051
    Annual Cost of Treatment1061
    Treatment Usage Patterns1071
      Diseased Population1081
      Treatment Seeking Population1081
      Diagnosis Population1081
      Prescription Population1081
  Drivers and Restraints to Multiple Sclerosis Therapeutics Market1091
    Drivers for Multiple Sclerosis Market1091
      Launch of Several High-priced Novel Disease-modifying Therapies1091
      Increased Prescription Population1091
    Restraints for Multiple Sclerosis Market1101
      Patient Affordability and Reimbursement Issue1101
      Patent Expiry of Major Drugs Is Expected to Cause Market Decline1101
  Parkinson s Disease1101
    Introduction1101
      Treatment Algorithm1111
    Revenue1121
      Revenue by Country1131
      Generic Share1141
    Annual Cost of Treatment1151
    Treatment Usage Patterns1161
      Diseased Population1171
      Treatment Seeking Population1171
      Diagnosis Population1171
      Prescription Population1171
  Drivers and Restraints to Parkinson s Disease Therapeutics Market1181
    Drivers for the Parkinson s disease Therapeutics Market1181
      Rise in Geriatric Population and Increase in Life Expectancy1181
    Restraints for the Parkinson s disease Therapeutics Market1181
      Lack of Definite Diagnostic Techniques Delays Treatments of PD1181
      Patent Expiry in Upcoming Years Will Affect the Market Growth1181
  Schizophrenia1191
    Introduction1191
      Treatment Algorithm1201
    Revenue1211
      Revenue by Country1221
      Generic Share1231
    Annual Cost of Treatment1241
    Treatment Usage Pattern1251
      Diseased Population1261
      Treatment Seeking Population1261
      Diagnosis Population1261
      Prescription Population1261
  Drivers and Barriers to Schizophrenia Market1271
    Drivers for Schizophrenia Market1271
      Disease Population Growth1271
      Expected Launch of Pipeline Molecules1271
    Barriers for Schizophrenia Market1281
      Low Treatment Seeking Behavior1281
      Patent Expiries of Major Drugs1281
  Major Depressive Disorder (MDD)1281
    Introduction1281
      Treatment Algorithm1291
    Revenue1301
      Revenue by Country1311
      Generic Share1321
    Annual Cost of Treatment1331
    Treatment Usage Patterns1341
      Diseased Population1351
      Treatment Seeking Population1351
      Diagnosis Population1351
      Prescription Population1351
  Drivers and Barriers to MDD Market1361
    Drivers for MDD Market1361
      New launches1361
    Barriers for MDD Market1361
      Non compliance to Drug Therapy and Side Effects of the Antidepressants1361
      Misdiagnosis1371
      Alternative Therapy for MDD1371
Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis13860
  Introduction1381
    Product Pipeline by Indication1381
    Product Pipeline by Clinical Stage of Development1391
    Introduction14010
  Attention Deficit Hyperactivity Disorder (ADHD)1501
    Introduction1503
  Bipolar Disorder1531
    Introduction1532
  Diabetic Neuropathy1551
    Introduction1552
  Epilepsy1571
    Introduction1574
  Insomnia1611
    Introduction1612
  Major Depressive Disorder (MDD)1631
    Introduction1634

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010" Nov 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Central-Nervous-System-Disorders-Therapeutics-Market-to-2017-Multiple-Sclerosis-Major-Depressive-Disorder-and-Schizophrenia-Accounted-for-Half-the-Market-Value-in-2010-2115-285>
  
APA:
GBI Research Reports. (2011). Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 Nov 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Central-Nervous-System-Disorders-Therapeutics-Market-to-2017-Multiple-Sclerosis-Major-Depressive-Disorder-and-Schizophrenia-Accounted-for-Half-the-Market-Value-in-2010-2115-285>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.